dx 8951 has been researched along with Adenocarcinoma in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Coyle, J; DeJager, R; Hoff, PM; Pazdur, R; Rowinsky, EK; Royce, ME; Saltz, LB | 1 |
Abou-Alfa, GK; Becerra, CR; De Jager, R; Eckhardt, SG; Feit, K; Kelsen, DP; O'Reilly, EM; Patt, YZ; Rowinsky, EK; Schwartz, GK; Sharma, S; Siegel, E | 1 |
Ajani, JA; Baez, L; Becerra, CR; Cohn, A; De Jager, R; Feit, K; Kamida, M; Major, P; Silva, A; Takimoto, C | 1 |
3 trial(s) available for dx 8951 and Adenocarcinoma
Article | Year |
---|---|
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Male; Middle Aged; Rectal Neoplasms | 2004 |
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Area Under Curve; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Drug Administration Schedule; Female; Gallbladder Neoplasms; Half-Life; Humans; Male; Middle Aged; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2005 |
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Stomach Neoplasms; Treatment Outcome | 2005 |